Adaptive biotechnologies stock.
Adaptive Biotechnologies Corp. ( NASDAQ: ADPT) stock is down over 72% in the previous 52-weeks and 58.5% YTD. Since its inception, the company has been a loss-maker. Still, the revenues have been ...
The stock price for . Adaptive Biotechnologies (NASDAQ: ADPT) is $4.4 last updated Today at November 30, 2023 at 9:44 PM UTC. Q Does Adaptive Biotechnologies (ADPT) pay a dividend?Adaptive Biotechnologies Stock Performance. NASDAQ:ADPT opened at $4.33 on Tuesday. The firm’s fifty day moving average is $4.59 and its two-hundred day moving average is $6.13. Adaptive Biotechnologies Co. has a one year low of $2.61 and a one year high of $10.79. The firm has a market cap of $626.85 million, a price-to …Jul 21, 2023 · Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of July 21, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.08. Adaptive Biotechnologies Corp is up 4.94% from its previous closing price of $7.70. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.60 and $7.79. Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of July 21, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.08. Adaptive Biotechnologies Corp is up 4.94% from its previous closing price of $7.70. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.60 and $7.79.
SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended ...
Looking for the best gutter downspout adapters and components? We put together the top 8 models for your next gutter project. Expert Advice On Improving Your Home Videos Latest View All Guides Latest View All Radio Show Latest View All Podc...Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...
The average twelve-month price prediction for Adaptive Biotechnologies is $9.50 with a high price target of $15.00 and a low price target of $6.00. Learn more on ADPT's analyst rating history. Do Wall Street analysts like Adaptive Biotechnologies more than its competitors? Analysts like Adaptive Biotechnologies less than other Medical companies.Second Quarter 2023 Financial Results. Revenue was $48.9 million for the quarter ended June 30, 2023, representing a 12% increase from the second quarter in the prior year. Immune Medicine revenue was $23.0 million for the quarter, representing a 3% increase from the second quarter in the prior year.Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Lik Wee Lee. Employment: Adaptive Biotechnologies. Crystal L. Mackall. Stock and Other Ownership Interests: Lyell Immunopharma, Alimera Sciences, Vor Pharmaceuticals, Apricity Health, Syncopation …Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic …Piper Sandler Reaffirms Their Buy Rating on Adaptive Biotechnologies (ADPT) November 10, 2023TipRanks. Adaptive Biotechnologies price target lowered to $7 from $11 at BTIG November 10 ...
Adaptive Biotechnologies Corporation (ADPT.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Adaptive Biotechnologies ...
On average, Wall Street analysts predict. that Adaptive Biotechnologies's share price could reach $8.00 by Nov 13, 2024. The average Adaptive Biotechnologies stock price prediction forecasts a potential upside of 83.07% from the current ADPT share price of $4.37.
Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s traded shares stood at 0.53 million during the last session, with the company’s beta value hitting 1.21. At the close of trading, the stock’s price was $4.21, to imply a decrease of -0.94% or -$0.04 in intraday trading. The ADPT share’s 52-week ...Ms. Taylor ADPT stock SEC Form 4 insiders trading. Stacy has made over 25 trades of the Adaptive Biotechnologies stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 18,878 units of ADPT stock worth $162,162 on 6 March 2023.. The largest trade she's ever made was exercising 19,580 units of Adaptive …SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the ...Nov 30, 2023 · Valuation metrics show that Adaptive Biotechnologies Corporation may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth ... Adaptive Biotechnologies Corporation (ADPT.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock Adaptive Biotechnologies ...Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Maneesh Tandon. Employment: Roche (I) Stock and Other Ownership Interests: Roche Pharma AG. Anna-Maria Fink. Research Funding: Celgene/Bristol Myers Squibb (Inst), AstraZeneca (Inst)Adaptive Biotechnologies Corp’s Stock Price as of Market Close. As of July 21, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.08. Adaptive Biotechnologies Corp is up 4.94% from its previous closing price of $7.70. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $7.60 and $7.79.
Nov 7, 2023 · SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to assess ... Adaptive Biotechnologies. Cathie Wood has bought almost 10 million shares of this stock for her Ark Genomic Revolution fund. Adaptive Biotechnologies Corp. ( NASDAQ: ADPT ) is a commercial-stage ...The Adaptive Biotechnologies stock prediction for 2025 is currently $ 3.58, assuming that Adaptive Biotechnologies shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -19.24% increase in the ADPT stock price.Apr 25, 2023 · Adaptive Biotechnologies Corp is down 9.82% from its previous closing price of $8.25. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.20 and $8.61. Currently, there are 143.06 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive Biotechnologies Corp’s P ... Before we jump into Adaptive Biotechnologies Corp’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background. Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to …
Track Adaptive Biotechnologies Corp (ADPT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors
In summary, Adaptive Biotechnologies Corp (ADPT) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.May 3, 2023 · Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.44 per share a year ago. These ... Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of its clonoSEQ ® Assay to detect minimal residual disease ...If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.Adaptive Biotechnologies (ADPT) Stock Forecast & Price TargetSep 30, 2022 · 2022 Financial Guidance. Adaptive Biotechnologies narrows full year 2022 revenue to be in the range of $185 million to $190 million compared to the previous expectation of $185 million to $195 million. We now expect full year 2022 operating expenses to be below $400 million compared to the previous expectation of between $410 million and $415 ... Adaptive is powering immune medicine in the most unique way—and we’re looking for individuals who want to build a story, not just a resume. If you want to go beyond the impossible—Adaptive is where you’ll discover your story. You’ll tackle big, interesting, highly impactful problems that lead to a future you can help write.As of March 31, 2023, 4:00 PM CST, Adaptive Biotechnologies Corp’s stock price was $8.83. Adaptive Biotechnologies Corp is up 4.87% from its previous closing price of $8.42. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.21 and $8.67. Currently, there are 143.06 million shares of Adaptive ...The advantages of biotechnology include curing infectious diseases, creating more efficient fuels and increasing farming yields to feed more people. Disadvantages of biotechnology include antibiotic resistant bacteria, new allergic reaction...
Adaptive Biotechnologies Corporation announces a multi-year collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ® assay technology across the company’s pipeline of treatments for patients with lymphoid malignancies. This collaboration aims to support the clinical development and potential …
ADPT Earnings Date and Information. Adaptive Biotechnologies last announced its earnings data on November 9th, 2023. The reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.03. The business earned $37.92 million during the quarter, compared to analyst estimates of $43.26 million.
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 7.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?6. Adaptive Biotechnologies -- $6 a share. Adaptive Biotechnologies ( ADPT 6.95%) may get cheaper in the short-term, but this biotech has an exciting platform that should unlock a lot of value ...Adaptive Biotechnologies has an immune medicine platform used for sequencing T cells and developing a wide array of diagnostic and clinical products. ... If a stock tanks 80%, ...52 Week Low. Data Provided by Refinitiv. Minimum 15 minutes delayed. RSS Feeds.Looking for the best gutter downspout adapters and components? We put together the top 8 models for your next gutter project. Expert Advice On Improving Your Home Videos Latest View All Guides Latest View All Radio Show Latest View All Podc...Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...Phone Number (206) 659-0067. Adaptive Biotechnologies is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clone-SEQ, is a test authorized by the FDA for the detection …Adaptive Biotechnologies Chief Scientific Officer Harlan Robins signs the final beam during a “topping off” ceremony at the company’s future headquarters on Thursday, 23, 2020 in Seattle ...Stock analysis for Adaptive Biotechnologies Corp (ADPT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings …Adaptive Biotechnologies Corporation announces a multi-year collaboration with BeiGene to assess minimal residual disease (MRD) using clonoSEQ® assay technology across the company’s pipeline of treatments for patients with lymphoid malignancies. This collaboration aims to support the clinical development and potential …Shares of Adaptive Biotechnologies ... The clinical-stage biotech company's stock closed last week at $7.31, then rose to as high as $9.08 on Wednesday. The stock is up a little more than 10% so ...
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to …View today's Adaptive Biotechnologies Corp stock price and latest ADPT news and analysis. Create real-time notifications to follow any changes in the live stock price.4.3500. -0.1600. -3.55%. SEATTLE, April 06, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company ...Instagram:https://instagram. tax free municipal bond ratesnames for llcvenezuela oil productioncertified financial planner software Adaptive is powering immune medicine in the most unique way—and we’re looking for individuals who want to build a story, not just a resume. If you want to go beyond the impossible—Adaptive is where you’ll discover your story. You’ll tackle big, interesting, highly impactful problems that lead to a future you can help write.Wood has been adding to Adaptive Biotechnologies -- with a market cap barely above $1 billion -- in recent days. Homing in on immune-system genetic sequencing technology, Adaptive hasn't had a ... delta dental cover veneersvanguard mid cap index fund Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Lik Wee Lee. Employment: Adaptive Biotechnologies. Crystal L. Mackall. Stock and Other Ownership Interests: Lyell Immunopharma, Alimera Sciences, Vor Pharmaceuticals, Apricity Health, Syncopation …Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%. betr stock nyse Valuation metrics show that Adaptive Biotechnologies Corporation may be overvalued. Its Value Score of F indicates it would be a bad pick for value investors. The financial health and growth ...The Investor Relations website contains information about Adaptive Biotechnologies's business for stockholders, potential investors, and financial analysts.